Almirall names new executive director for research

Almirall has announced that Dr Bertil Lindmark has been appointed as its new executive director for research and development.

Dr Lindmark brings more than 20 years' worth of pharmaceutical industry experience to the company, with extensive expertise in the respiratory field and qualifications in the area of gastric diseases.

Formerly, he held the positions of vice-president and head of clinical development and global vice-president for respiratory and inflammation at fellow healthcare company AstraZeneca's Japanese division.

He joins Almirall in order to replace previous research and development director Dr Per-Olof Andersson, who recently announced his retirement.

A statement from the company said: "This appointment strengthens Almirall's research and development team in areas that are of particular interest to the company."

Earlier this month, Almirall and development partner Forest Laboratories published positive data from a phase III clinical trial of aclidinium bromide, a developmental therapy for moderate to severe chronic obstructive pulmonary disease.